Abbisko Cayman Past Earnings Performance

Past criteria checks 0/6

Abbisko Cayman has been growing earnings at an average annual rate of 3.6%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 23.4% per year.

Key information

3.6%

Earnings growth rate

88.8%

EPS growth rate

Biotechs Industry Growth11.0%
Revenue growth rate23.4%
Return on equity-21.8%
Net Margin-2,264.3%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Here's Why We're Not Too Worried About Abbisko Cayman's (HKG:2256) Cash Burn Situation

Apr 27
Here's Why We're Not Too Worried About Abbisko Cayman's (HKG:2256) Cash Burn Situation

An Intrinsic Calculation For Abbisko Cayman Limited (HKG:2256) Suggests It's 37% Undervalued

Jan 09
An Intrinsic Calculation For Abbisko Cayman Limited (HKG:2256) Suggests It's 37% Undervalued

Will Abbisko Cayman (HKG:2256) Spend Its Cash Wisely?

Nov 01
Will Abbisko Cayman (HKG:2256) Spend Its Cash Wisely?

We Think Abbisko Cayman (HKG:2256) Can Afford To Drive Business Growth

Jun 08
We Think Abbisko Cayman (HKG:2256) Can Afford To Drive Business Growth

Revenue & Expenses Breakdown

How Abbisko Cayman makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:2256 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2319-43296434
30 Sep 2319-457102429
30 Jun 2319-483108424
31 Mar 2310-489113402
31 Dec 220-496118379
30 Sep 2211-1,075129342
30 Jun 2223-1,654140306
31 Mar 2223-1,797144268
31 Dec 2123-1,810125226
31 Mar 217-77426155
31 Dec 200-70721133
31 Dec 194-1342281

Quality Earnings: 2256 is currently unprofitable.

Growing Profit Margin: 2256 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2256 is unprofitable, but has reduced losses over the past 5 years at a rate of 3.6% per year.

Accelerating Growth: Unable to compare 2256's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2256 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).


Return on Equity

High ROE: 2256 has a negative Return on Equity (-21.79%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.